Carcinotech dominates summer awards season Image Credit: Carcinotech Over the past six years, Carcinotech has been laser-focused on developing, optimizing and commercializing our innovative drug development platform.During this period, we have significantly invested in cutting-edge imaging and bioprinting technology and recruited highly specialized staff from leading academic institutes and industry.This focus has led to unparalleled expertise in oncology, bioengineering, and assay development, along with several pending international patents for our technology.
The recognition we have received this summer is a testament to our relentless hard work and we are honoured by the accolades that celebrate the significant strides we are making. Here’s a roundup of the recent awards we have proudly received: Best EIS investee company of the year, EISA 2024 – Carcinotech We are delighted to have been recognized as the Best EIS Investee Company of the Year at the Enterprise Investment Scheme Awards 2024.The Enterprise Investment Scheme (EIS) facilitates the smooth flow of risk equity capital from private individuals to early-stage businesses, offering them vital support to enable growth.
These awards recognize the outstanding achievements of participants in the scheme and we’re grateful for the recognition and the unwavering support from the EIS.This award also underscores our commitment to innovation, growth, and delivering excellent service to our clients. Entrepreneur of the ye.